Cart is empty New research led by a St. Michael’s Hospital clinician-scientist and published in the New England Journal of Medicine suggests that a therapy called Tolebrutinib could reduce disability progression in people with non-relapsing progressive multiple sclerosis (MS)—a subtype of MS that doesn’t respond well to current disease-modifying therapies.
Leave A Comment